GSK gives up on Horizant as XenoPort decides to go it alone
This article was originally published in Scrip
GlaxoSmithKline and XenoPort have decided to resolve their differences over Horizant (gabapentin enacarbil) extended-release tablets by terminating their collaboration. XenoPort now intends to hire a contract sales force in an attempt to do a better job on its own of commercialising the product.
You may also be interested in...
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.